- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02869672
Safety and Immunogenicity Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old
August 16, 2016 updated by: Beijing Chaoyang District Centre for Disease Control and Prevention
This study evaluates the safety and immunogenicity of the ACYW135 Meningococcal Polysaccharide Vaccine in population aged 2-50 years old.
Subjects will be divided into 3 group according to their age, receiving the test vaccine and the control vaccine at the proportion of 1:1 randomly.
Each age group has 400 subjects, 1200 in total.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
1200
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 50 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- With the subject (or his guardian's) informed consent and signed the informed consent;
- The history, physical examination and clinical judgement were determined to be healthy and in accordance with the vaccination age of the product;
- The Subject or his guardian could comply with the clinical study protocol;
- Have not been inoculated with Meningococcal vaccine in the past six months and A + C meningococcal polysaccharide vaccine in the past two years;
- Have not been inoculated with other preventive biological products;
- Axillary temperature≤37.0 ℃.
Exclusion Criteria:
- Children with the history of Neisseria meningitis;
- Had allergies or serious adverse reactions of previous vaccination, such as allergies, urticaria, dyspnea, edema, abdominal pain, etc;
- Had immune inhibitor therapy and cytotoxic therapy, inhaled corticosteroids in the past 6 months (not including allergic rhinitis corticosteroid aerosol therapy, patients with acute non concurrent dermatitis surface corticosteroid therapy);
- Have been accepted blood products in the past 3 months;
- Have been inoculated with other research drugs or vaccines in the past month;
- Have been inoculated with attenuated live vaccine in the past 14 days;
- Have been inoculated with subunit or inactivated vaccine in the past 7 days;
- Had any acute illness, the need for systemic application of antibiotics or antiviral treatment in the past 7 days;
- Had fever in the past 3 days (axillary temperature≥38.0℃) ;
- Have been diagnosed with abnormal coagulation function (such as the lack of coagulation factors, coagulation disorders and abnormal blood platelet), obvious bruises or coagulation disorders by physician diagnosis;
- Had the history of thyroid resection or the need for treatment of thyroid diseases in the past 12 months;
- Asplenia, functional asplenia and asplenia or splenectomy of any situation;
- Had epilepsy, convulsions, encephalopathy, mental illness or family history;
- Suffering from serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia, neurological disorders or Guillain-Barre syndrome);
- Suffering from known or suspected concurrent diseases including: respiratory diseases, acute or chronic infection of the activities, children's mother or the subject had HIV infection, cardiovascular disease, high blood pressure, during cancer treatment period, skin diseases;
- The female during her pregnant and lactation period or who plan to become pregnant during the trial.
- The subject of any other factors that are not suitable to participate in clinical trials according to the researcher's judgment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: age of 18-50 years old, experimental
0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
|
Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
|
Active Comparator: age of 18-50 years old, control
0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
|
Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
|
Experimental: age of 7-17 years old,experimental
0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
|
Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
|
Active Comparator: age of 7-17 years old, control
0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
|
Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
|
Experimental: age of 2-6 years old,experimental
0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
|
Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
|
Active Comparator: age of 2-6 years old,control
0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
|
Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate serum antibody titers of quadrivalent influenza Vaccine in healthy people.
Time Frame: 28 days
|
The serum antibody titers will be evaluated at 28 days after vaccination.
|
28 days
|
Evaluate the Rate of Adverse reactions of quadrivalent influenza Vaccine in healthy people.
Time Frame: 28 days
|
Adverse reactions associated with vaccine will be observed in subjects after vaccination.
Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site.
solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy.
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2016
Primary Completion (Anticipated)
December 1, 2016
Study Registration Dates
First Submitted
August 12, 2016
First Submitted That Met QC Criteria
August 12, 2016
First Posted (Estimate)
August 17, 2016
Study Record Updates
Last Update Posted (Estimate)
August 18, 2016
Last Update Submitted That Met QC Criteria
August 16, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- cycdc2016-5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ACYW135 Meningococcal Polysaccharide Vaccine
-
University of FloridaCompletedMeningococcal VaccineUnited States
-
International Centre for Diarrhoeal Disease Research...Incepta Vaccine LimitedCompletedMeningococcal VaccineBangladesh
-
PfizerCompletedMeningococcal VaccineUnited States, Canada, Finland, Italy, Poland, United Kingdom, Czech Republic, Germany
-
PfizerCompletedMeningococcal VaccineFinland, Spain, Poland
-
PfizerCompletedMeningococcal VaccineUnited States
-
PfizerCompletedMeningococcal VaccineUnited States, Finland, Czechia, Poland
-
PfizerCompletedMeningococcal VaccineUnited States, Denmark, Hungary, Czechia, Poland
-
PfizerCompletedMeningococcal VaccineSpain, Germany, Finland, Czechia, Poland, Denmark, Sweden
-
Assistance Publique - Hôpitaux de ParisCompletedHematopoietic Stem Cell Transplant | Meningococcal VaccineFrance
-
PfizerTerminatedMeningococcal VaccineSpain, Germany, Greece
Clinical Trials on Tiantan Biology ACYW135 meningococcal polysaccharide vaccine
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActive, not recruiting
-
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.Not yet recruitingMeningococcal MeningitisChina
-
Beijing Chaoyang District Centre for Disease Control...Completed
-
Hualan Biological Engineering, Inc.Completed
-
Hualan Biological Engineering, Inc.Completed
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActive, not recruitingMeningitis, MeningococcalChina
-
Hualan Biological Engineering, Inc.Completed
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdCompletedMeningitis, MeningococcalChina
-
Beijing Minhai Biotechnology Co., LtdCompleted
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdAir Force Military Medical University, China; Guangxi Center for Disease Control... and other collaboratorsUnknownMeningitis, MeningococcalChina